# Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

> **NCT04859569** · PHASE3 · UNKNOWN · sponsor: **Luye Pharma Group Ltd.** · enrollment: 850 (estimated)

## Conditions studied

- Bone Metastases From Solid Tumors

## Interventions

- **DRUG:** LY01011
- **DRUG:** Xgeva®

## Key facts

- **NCT ID:** NCT04859569
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-30
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 850 (ESTIMATED)
- **Last updated:** 2021-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04859569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04859569, "Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04859569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*